INT90960

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.50
First Reported 2000
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 9
Total Number 9
Disease Relevance 2.06
Pain Relevance 2.76

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (CYP2D6) small molecule metabolic process (CYP2D6) oxidoreductase activity (CYP2D6)
endoplasmic reticulum (CYP2D6)
Anatomy Link Frequency
body 4
bands 2
respiratory 2
CYP2D6 (Homo sapiens)
Pain Link Frequency Relevance Heat
fluoxetine 58 99.84 Very High Very High Very High
Opioid 166 99.30 Very High Very High Very High
Morphine 80 97.74 Very High Very High Very High
Codeine 4 97.50 Very High Very High Very High
analgesia 21 94.48 High High
tramadol 4 92.48 High High
depression 85 88.36 High High
Dextromethorphan 33 82.28 Quite High
sSRI 88 81.36 Quite High
antagonist 80 79.28 Quite High
Disease Link Frequency Relevance Heat
Breast Cancer 10 99.48 Very High Very High Very High
Toxicity 4 99.48 Very High Very High Very High
Pressure Volume 2 Under Development 7 94.76 High High
Respiratory Failure 1 88.84 High High
Depression 98 85.24 High High
Hot Flashes 2 84.40 Quite High
Recurrence 12 74.08 Quite High
Cancer Pain 36 71.20 Quite High
Hypersensitivity 3 69.80 Quite High
Headache 11 68.32 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Under what circumstances should patients considering tamoxifen as an adjuvant therapy be tested for CYP2D6 and under what circumstances should patients taking tamoxifen avoid potent inhibitors of CYP2D6?
Positive_regulation (for) of Gene_expression (tested) of CYP2D6
1) Confidence 0.50 Published 2007 Journal Breast Cancer Res Section Body Doc Link PMC1868921 Disease Relevance 0.48 Pain Relevance 0.08
Under what circumstances should patients considering tamoxifen as an adjuvant therapy be tested for CYP2D6 and under what circumstances should patients taking tamoxifen avoid potent inhibitors of CYP2D6?
Positive_regulation (circumstances) of Gene_expression (tested) of CYP2D6
2) Confidence 0.50 Published 2007 Journal Breast Cancer Res Section Body Doc Link PMC1868921 Disease Relevance 0.50 Pain Relevance 0.08
However, according to the RR spectra of the ferrous active and inactive forms previously reported for other CYPs, the active enzyme still contributes to a significant extent to the observed CYP2D6 SERRS spectrum, whereas no marker bands for the inactive species other than the one at 1,360 cm?
Positive_regulation (contributes) of Gene_expression (spectrum) of CYP2D6 SERRS in bands
3) Confidence 0.49 Published 2007 Journal J Biol Inorg Chem Section Body Doc Link PMC2099460 Disease Relevance 0 Pain Relevance 0.03
The drug is widely distributed in the body, with low protein binding and a high volume of distribution (see Table 2).118,119 Following oral absorption, venlafaxine undergoes extensive first-pass hepatic metabolism, where conversion to the active metabolite, desvenlafaxine, occurs via demethylation.157 This reaction is mediated by CYP2D6.120 Desvenlafaxine is further metabolized by CYP3A4.122 Other metabolic pathways for venlafaxine include N-demethylation which is probably mediated by CYP3A4.157 CYP2C9 and CYP2C19 isoenzymes may also be involved in the metabolic pathways of both drugs.121
Positive_regulation (by) of Gene_expression (metabolized) of CYP2D6 in body
4) Confidence 0.48 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2938284 Disease Relevance 0 Pain Relevance 0.20
The drug is widely distributed in the body, with low protein binding and a high volume of distribution (see Table 2).118,119 Following oral absorption, venlafaxine undergoes extensive first-pass hepatic metabolism, where conversion to the active metabolite, desvenlafaxine, occurs via demethylation.157 This reaction is mediated by CYP2D6.120 Desvenlafaxine is further metabolized by CYP3A4.122 Other metabolic pathways for venlafaxine include N-demethylation which is probably mediated by CYP3A4.157 CYP2C9 and CYP2C19 isoenzymes may also be involved in the metabolic pathways of both drugs.121
Positive_regulation (by) of Gene_expression (metabolized) of CYP2D6 in body
5) Confidence 0.48 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2938284 Disease Relevance 0 Pain Relevance 0.20
As previously observed [27], in the RR spectrum of wild-type CYP2D6 ?
Positive_regulation (spectrum) of Gene_expression (spectrum) of CYP2D6
6) Confidence 0.43 Published 2007 Journal J Biol Inorg Chem Section Body Doc Link PMC1915625 Disease Relevance 0 Pain Relevance 0.07
Together, these findings suggest a significant role for the polymorphically expressed CYP2D6 in fluoxetine clearance and are consistent with reports on the clinical pharmacokinetics of fluoxetine.
Positive_regulation (role) of Gene_expression (expressed) of CYP2D6 associated with fluoxetine
7) Confidence 0.39 Published 2000 Journal Drug Metab. Dispos. Section Abstract Doc Link 10997938 Disease Relevance 0 Pain Relevance 0.64
These are known as “poor metabolizers” and thus experience little analgesia from codeine, as compared to “extensive metabolizers.32 CYP2D6 gene duplication on the other hand is associated with ultra-rapid metabolism of codeine to morphine, found in 3% of Caucasians.33 There is a case report of fatal neonatal opioid toxicity in a child who was being breastfed by a CYP2D6 ultra-rapid metabolizing mother.34,35 Variation in at least 16 alleles has been shown to influence CYP2D6 activity.36 Recent data suggest that CYP2D6 phenotype also plays a role in response to tramadol.37 CYP2D6 gene duplication has been described as playing a role in development of respiratory depression on tramadol.38
Positive_regulation (breastfed) of Gene_expression (ultra) of CYP2D6 in respiratory associated with tramadol, toxicity, depression, respiratory failure, opioid, morphine, codeine and analgesia
8) Confidence 0.37 Published 2009 Journal Journal of pain research Section Body Doc Link PMC3004622 Disease Relevance 0.26 Pain Relevance 1.26
Palonosetron does not cause inhibition or induction of the main hepatic enzyme systems including CYP2D6, CYP1A2 and CYP3A4/5, so the risk of significant drug interactions is low.119 However an adverse reaction with apomorphine that presented as profound hypotension and altered consciousness has been reported, so concomitant use is contraindicated.128


Positive_regulation (including) of Gene_expression (/) of CYP2D6 associated with pressure volume 2 under development
9) Confidence 0.28 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697527 Disease Relevance 0.82 Pain Relevance 0.19

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox